Home » Newsletters » BioWorld Science

BioWorld Science

June 20, 2007

View Archived Issues

Recent clinical data on nilotinib in leukemia presented

Snapshots of agents under study in Alzheimer's disease

Malaria vaccine AMA1 studied in phase Ib trial in Mali

New results with therapies under development for Parkinson's disease

Recent Tibotec and Bristol-Myers Squibb patents report novel therapeutic agents for HIV infection

New agents for treating neurological disorders disclosed in recent patent literature

Recent patents report novel therapeutic agents for metabolic disorders

NOV-002 slows disease progression in platinum-resistant ovarian cancer

Positive topline findings for balsalazide tablets

FDA grants orphan drug status to Immtech's pafuramidine

Keryx completes patient randomization for Sulonex phase III study

Chugai to explore safety of oseltamivir

Findings for new powder form of Renvela

IC31 adjuvanted flu vaccine begins phase I trials

Lexicon announces long-term financial agreements with Invus and Symphony

Peptech restructures agreement with Biosceptre

Sativex receives Qualifying Notice from Health Canada for cancer pain

Genta to request review of Genasense's non-approvable status

Collegium files IND for abuse deterrent opioid COL-003

Terutroban exhibits beneficial effects in rat models of stroke

FDA accepts for review GlaxoSmithKline's DTaP-IPV combination vaccine

Preclinical studies on drugs under development for Parkinson's disease

Telcyta clinical hold converted to partial hold

Nexavar submitted in E.U. for hepatocellular carcinoma

Ixabepilone NDA granted priority review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 2, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...